deucravacitinib (Rx)

Brand and Other Names:Sotyktu

Dosing & Uses


Dosage Forms & Strengths


  • 6mg

Plaque Psoriasis

Indicated for moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy

6 mg PO qDay

Dosage Modifications

Renal impairment

  • Mild, moderate, or severe or patients with end-stage renal disease on dialysis: No dosage adjustment necessary

Hepatic impairment

  • Mild-to-moderate (Child-Pugh A or B): No dosage adjustment necessary
  • Severe (Child-Pugh C): Not recommended

Dosing Considerations

Limitation of use: Not recommended for use in combination with other potent immunosuppressants

Before initiating treatment

  • Evaluate for tuberculosis (TB); if positive, start TB treatment before initiating
  • Update immunizations according to current immunization guidelines

Safety and efficacy not established



Interaction Checker

and deucravacitinib

No Results

     activity indicator 
    No Interactions Found
    Interactions Found


      Serious - Use Alternative

        Significant - Monitor Closely


            All Interactions Sort By:
             activity indicator 

            Contraindicated (0)

              Serious - Use Alternative (1)

              • ublituximab

                ublituximab and deucravacitinib both increase immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.

              Monitor Closely (0)

                Minor (0)


                  Adverse Effects


                  Infections (29%)

                  Upper respiratory tract infections (19.2%)


                  Blood creatine phosphokinase increased (2.7%)

                  Herpes simplex (2%)

                  Mouth ulcers (1.9%)

                  Folliculitis (1.7%)

                  Acne (1.4%)


                  Herpes zoster




                  Hypersensitivity to deucravacitinib or any of excipients in drug product


                  Hypersensitivity reactions (eg, angioedema) have been reported; if a clinically significant reaction occurs, discontinue therapy

                  Evaluate for TB before initiating

                  Malignancies, including lymphomas, were observed; consider the benefits and risk for individual, particularly in patients with a known malignancy (other than a successfully treated non-melanoma skin cancer) and patients who develop a malignancy during treatment

                  Cases of rhabdomyolysis reported resulting in interrupting or discontinuing therapy; discontinue therapy if markedly elevated CPK levels occur or myopathy is diagnosed or suspected; advise patients to promptly report any unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever

                  May increase triglyceride levels; monitor and manage according to clinical guidelines for hyperlipidemia

                  Elevated liver enzymes have been reported; evaluate liver enzymes at baseline and then monitor in patients with known or suspected liver disease; if liver enzymes increase or drug-induced liver injury suspected; interrupt therapy until liver injury is ruled out

                  Before initiating, consider completion of all age-appropriate immunizations according to current immunization guidelines including prophylactic herpes zoster vaccination


                  • May increase infection risk; avoid use with active or serious infections, including localized infections
                  • Closely monitor for developing signs and symptoms of infection during and after treatment
                  • If infection develops, promptly evaluate and complete diagnostic testing
                  • Initiate appropriate antimicrobial therapy and closely monitor
                  • Interrupt therapy if serious infection develops; do not resume until infection resolves or is adequately treated
                  • Consider risks and benefits of therapy before initiating in patients
                    • With chronic or recurrent infection
                    • Who have been exposed to tuberculosis
                    • With a history of a serious or an opportunistic infection
                    • With underlying conditions that may predispose them to infection
                  • Viral reactivation
                    • Herpes virus reactivation (eg, herpes zoster, herpes simplex), was reported
                    • Impact on chronic viral hepatitis reactivation is unknown
                    • Patients who tested positive for hepatitis B or C, chronic hepatitis B, or untreated hepatitis C were excluded from clinical trials
                    • Consider viral hepatitis screening and monitoring for reactivation in accordance with clinical guidelines before initiating and during therapy
                    • If signs of reactivation occur, consult a hepatitis specialist
                    • Not recommended for use in patients with active hepatitis B or hepatitis C

                  Potential risks related to Janus kinase (JAK) inhibitors

                  • Unknown whether TYK2 inhibition may be associated with the observed or potential adverse reactions of JAK inhibition
                  • In a safety trial of a JAK inhibitor in rheumatoid arthritis (RA), patients aged ≥50 years with at least 1 cardiovascular risk factor, higher rates of all-cause mortality, including sudden cardiovascular death, major adverse cardiovascular events, overall thrombosis, deep venous thrombosis, pulmonary embolism, and malignancies (excluding non-melanoma skin cancer) were observed in patients treated with the JAK inhibitor
                  • Not approved for use in RA

                  Drug interaction overview

                  • Vaccinations
                    • Live vaccines: Avoid use
                    • Response to live or non-live vaccines not evaluated

                  Pregnancy & Lactation


                  Insufficient data are available from case reports on use during pregnancy to evaluate a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcome

                  Report pregnancies to Bristol-Myers Squibb Company’s Adverse Event reporting line at 1-800-721-5072

                  Animal data

                  • No effects on embryofetal development were observed with oral administration to rats and rabbits during organogenesis at doses that were at least 91x the maximum recommended human dose of 6 mg once daily


                  There are no data on drug presence in human milk, effects on breastfed infant, or effects on milk production

                  Present in rat milk; when a drug is present in animal milk, it is likely that it will be present in human milk

                  Pregnancy Categories

                  A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

                  B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

                  C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

                  D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

                  X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

                  NA: Information not available.



                  Mechanism of Action

                  Tyrosine kinase 2 (TYK2) inhibitor, which is a member of JAK family, binds to regulatory domain of TYK2 resulting in inhibitor of receptor-mediated active of TYK2 and its downstream activation of signal transducers and activators of transcription

                  TYK2 pairs with JAK1 to mediate multiple cytokine pathways and pairs with JAK2 to transmit signals as shown in cell-based assays

                  Precise mechanism linking inhibition of TYK2 enzyme to therapeutic effectiveness is unknown


                  Bioavailability: 99%

                  Peak plasma time: 2-3 hr

                  Peak plasma concentration

                  • Deucravacitinib: 45 ng/mL
                  • BMT-153261 (active metabolite): 5 ng/mL


                  • Deucravacitinib: 473 ng·hr/mL
                  • BMT-153261 (active metabolite): 95 ng·hr//mL


                  Vd (steady-state): 140 L

                  Protein bound: 82-90%

                  Blood-to-plasma concentration ratio: 1.26


                  Metabolized by CYP1A2 to form major metabolite BMT-153261 (accounts for ~20% of systemic exposure of total drug-related components)

                  Also, metabolized by CYP2B6, CYP2D6, carboxylesterase (CES) 2, and uridine glucuronyl transferase (UGT)1A9


                  Half-life: 10 hr

                  Renal clearance: 27-54 mL/minute


                  • Deucravacitinib: Urine (13%); feces (26%)
                  • BMT-153261: Urine (6%); feces (12%)



                  Oral Administration

                  Take with or without food

                  Do not crush, cut, or chew tablets


                  Store at 20-25°C (68-77°F); excursions permitted to 15-30°C (59-86°F)

                  Keep out of reach of children



                  No images available for this drug.

                  Patient Handout

                  A Patient Handout is not currently available for this monograph.


                  FormularyPatient Discounts

                  Adding plans allows you to compare formulary status to other drugs in the same class.

                  To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

                  Adding plans allows you to:

                  • View the formulary and any restrictions for each plan.
                  • Manage and view all your plans together – even plans in different states.
                  • Compare formulary status to other drugs in the same class.
                  • Access your plan list on any device – mobile or desktop.

                  The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

                  Tier Description
                  1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
                  2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
                  3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
                  4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
                  5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
                  6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
                  NC NOT COVERED – Drugs that are not covered by the plan.
                  Code Definition
                  PA Prior Authorization
                  Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
                  QL Quantity Limits
                  Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
                  ST Step Therapy
                  Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
                  OR Other Restrictions
                  Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
                  Additional Offers
                  Email to Patient



                  The recipient will receive more details and instructions to access this offer.

                  By clicking send, you acknowledge that you have permission to email the recipient with this information.

                  Email Forms to Patient



                  The recipient will receive more details and instructions to access this offer.

                  By clicking send, you acknowledge that you have permission to email the recipient with this information.

                  Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.